PDF Download - summitMD.com

More documents

Recommendations

Info

PDF-XChange Viewer w w w.docu-track.co m Click to buy NOW! Summary & Conclusions - 1 PDF-XChange Viewer w w w.docu-track.co m Click to buy NOW! • Primary endpoint (In-Stent LL at 12 months) met: BioFreedom SD non-inferior to Taxus. • In-Stent LL for BioFreedom SD (0.17 mm) demonstrated a trend towards superiority at 12 months compared to Taxus (0.35 mm). • Both BioFreedom SD and BioFreedom LD demonstrated sustained safety up to 12 months, including absence of stent thrombosis.
PDF-XChange Viewer w w w.docu-track.co m Click to buy NOW! Summary & Conclusions - 2 PDF-XChange Viewer w w w.docu-track.co m Click to buy NOW! • BioFreedom: first polymer-free drug coated stent demonstrating comparable efficacy in inhibiting NIH (as assessed by independent QCA analysis) vs. a currently available DES with durable polymer at 12 months in a randomized clinical trial. • Larger trial with longer term follow-up warranted to confirm these encouraging results.
Page 1 and 2: PDF-XChange Viewer w w w.docu-track
Page 9 and 10: All values are presented as median
Page 11 and 12: All values are presented as median
Page 13 and 14: (mm) PDF-XChange Viewer w w w.docu-
Page 15 and 16: (mm) PDF-XChange Viewer w w w.docu-
Page 17: PDF-XChange Viewer w w w.docu-track

PDF Download - summitMD.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?